Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

被引：90

作者：

Labrosse, B

Labernardière, JL

Dam, E

Trouplin, V

Skrabal, K

Clavel, F

Mammano, F

机构：

[1] Hop Bichat Claude Bernard, Unite Rech Antivirale, INSERM, U552, F-75018 Paris, France

[2] Viralliance SAS, Paris, France

来源：

JOURNAL OF VIROLOGY | 2003年 / 77卷 / 02期

关键词：

D O I：

10.1128/JVI.77.2.1610-1613.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human immunodeficiency virus type 1 plasma viruses from 29 entry inhibitor-naive patients were characterized for their susceptibilities to T-20, AMD3100, and RANTES. A strikingly wide range of susceptibilities to T-20 was observed that was influenced by coreceptor usage but not by the susceptibilities of the viruses to inhibitors that target the chemokine receptors or by polymorphisms in the gp41 N helix.

引用

页码：1610 / 1613

页数：4

共 50 条

[21] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
Acosta, EP
Kakuda, TN
Brundage, RC
Anderson, PL
Fletcher, CV
CLINICAL INFECTIOUS DISEASES, 2000, 30 : S151 - S159
[22] Resistance to human immunodeficiency virus type 1 protease inhibitors
Boden, D
Markowitz, M
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2775 - 2783
[23] Resistance to inhibitors of the human immunodeficiency virus type 1 integration
Hazuda, Daria J.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (05): : 513 - 518
[24] Cofactors for human immunodeficiency virus entry into primary macrophages
Collman, RG
Yi, YJ
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 : S422 - S426
[25] Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site
Heil, ML
Decker, JM
Sfakianos, JN
Shaw, GM
Hunter, E
Derdeyn, CA
JOURNAL OF VIROLOGY, 2004, 78 (14) : 7582 - 7589
[26] Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines
Hartley, O
Dorgham, K
Perez-Bercoff, D
Cerini, F
Heimann, A
Gaertner, H
Offord, RE
Pancino, G
Debré, P
Gorochov, G
JOURNAL OF VIROLOGY, 2003, 77 (12) : 6637 - 6644
[27] Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1
Van Baelen, Kurt
Salzwedel, Karl
Rondelez, Evelien
Van Eygen, Veerle
De Vos, Stephanie
Verheyen, Ann
Steegen, Kim
Verlinden, Yvan
Allaway, Graham P.
Stuyver, Lieven J.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) : 2185 - 2188
[28] Primary human immunodeficiency virus type 1 infection in pregnancy
Keerasuntonpong, A
Pitt, J
Gaut, PL
Daar, ES
OBSTETRICS AND GYNECOLOGY, 1999, 94 (05): : 844 - 844
[29] Inhibitors of human immunodeficiency virus type I
Hazuda, Daria J.
RETROVIROLOGY, 2006, 3
[30] Inhibitors of human immunodeficiency virus type I
Daria J Hazuda
Retrovirology, 3 (Suppl 1)

← 1 2 3 4 5 →